000520 — Samil Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapSucker Stock

Annual income statement for Samil Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	122,999	134,247	179,676	196,346	219,700
Cost of Revenue
Gross Profit	49,032	48,988	67,486	74,071	80,914
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	116,461	133,847	175,656	190,458	219,545
Operating Profit	6,538	400	4,020	5,888	154
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	1,198	-4,761	1,058	1,424	-3,613
Provision for Income Taxes
Net Income After Taxes	1,341	-5,347	-28.3	1,664	-5,629
Net Income Before Extraordinary Items
Net Income	1,341	-5,347	-28.3	1,664	-5,629
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	1,341	-5,347	-28.3	1,664	-5,629
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	101	-404	-10.4	65.3	-314
Dividends per Share